Karyopharm Therapeutics Inc.
KPTI
$1.62
-$0.08-4.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -11.86% | 16.83% | 11.58% | 13.57% | -11.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.86% | 16.83% | 11.58% | 13.57% | -11.35% |
| Cost of Revenue | -11.22% | -2.16% | -15.83% | -12.76% | -15.05% |
| Gross Profit | -17.11% | 98.71% | 220.46% | 744.11% | 38.64% |
| SG&A Expenses | -8.99% | -2.44% | -16.25% | -3.71% | -8.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.20% | -2.28% | -16.01% | -8.92% | -12.11% |
| Operating Income | 7.63% | 19.53% | 42.96% | 42.09% | 13.28% |
| Income Before Tax | -80.11% | 4.42% | -231.07% | -3.27% | -255.97% |
| Income Tax Expenses | -- | -97.22% | 38.53% | 21.43% | -40.30% |
| Earnings from Continuing Operations | -79.92% | 4.56% | -232.03% | -3.29% | -256.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.92% | 4.56% | -232.03% | -3.29% | -256.57% |
| EBIT | 7.63% | 19.53% | 42.96% | 42.09% | 13.28% |
| EBITDA | 7.35% | 19.38% | 42.87% | 42.37% | 13.27% |
| EPS Basic | 46.41% | 63.28% | -55.63% | 0.68% | -291.06% |
| Normalized Basic EPS | 46.35% | 63.22% | 39.46% | 0.69% | -67.13% |
| EPS Diluted | 46.32% | 55.38% | -55.67% | 0.68% | -45.40% |
| Normalized Diluted EPS | 46.35% | 67.25% | 39.46% | 0.69% | -113.22% |
| Average Basic Shares Outstanding | 235.71% | 159.91% | 113.34% | 3.99% | 6.83% |
| Average Diluted Shares Outstanding | 235.71% | 191.79% | 113.34% | 3.99% | -16.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |